Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation (Q38105123)

28 August 2017

Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation (English)

1 reference

stem cell transplantation

28 August 2017

1 reference

1 reference

Dario Campana

1

1 reference

28 August 2017

Wing Leung

series ordinal

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

9 May 2013

1 reference

British Journal of Haematology

28 August 2017

1 reference

28 August 2017

162

1 reference

28 August 2017

2

1 reference

28 August 2017

147-161

1 reference

Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Bl

28 August 2017

1 reference

21 January 2018

1 reference

Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation.

21 January 2018

1 reference

Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL.

21 January 2018

1 reference

Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?

21 January 2018

1 reference

Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.

21 January 2018

1 reference

Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing

21 January 2018

1 reference

Gene-marking to trace origin of relapse after autologous bone-marrow transplantation.

21 January 2018

1 reference

Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.

21 January 2018

1 reference

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia

21 January 2018

1 reference

Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?

21 January 2018

1 reference

Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.

21 January 2018

1 reference

Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands.

21 January 2018

1 reference

A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells

21 January 2018

1 reference

Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation

21 January 2018

1 reference

Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia

21 January 2018

1 reference

New markers for minimal residual disease detection in acute lymphoblastic leukemia

21 January 2018

1 reference

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

21 January 2018

1 reference

Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial

21 January 2018

1 reference

Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia.

21 January 2018

1 reference

Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia

21 January 2018

1 reference

Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden

21 January 2018

1 reference

Expansion of highly cytotoxic human natural killer cells for cancer cell therapy

21 January 2018

1 reference

Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors

21 January 2018

1 reference

Clinical relevance of MRD in children undergoing allogeneic stem cell transplantation for ALL.

21 January 2018

1 reference

Practical application of minimal residual disease assessment in childhood acute lymphoblastic leukaemia annotation

21 January 2018

1 reference

Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells

21 January 2018

1 reference

Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia

21 January 2018

1 reference

Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies.

21 January 2018

1 reference

High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival

21 January 2018

1 reference

Why Your New Cancer Biomarker May Never Work: Recurrent Patterns and Remarkable Diversity in Biomarker Failures

21 January 2018

1 reference

Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism.

21 January 2018

1 reference

EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations.

21 January 2018

1 reference

Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications

21 January 2018

1 reference

Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.

21 January 2018

1 reference

Determinants of antileukemia effects of allogeneic NK cells

21 January 2018

1 reference

High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia

21 January 2018

1 reference

Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia

21 January 2018

1 reference

DNMT3A Mutations in Acute Myeloid Leukemia

21 January 2018

1 reference

Extensive Histological and Cytological Survey of Patients with Acute Leukaemia in "Complete Remission"

21 January 2018

1 reference

Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.

21 January 2018

1 reference

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

21 January 2018

1 reference

Clinical significance of minimal residual disease detected by multidimensional flow cytometry: serial monitoring after allogeneic stem cell transplantation for acute leukemia.

21 January 2018

1 reference

Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation. Nagoya BMT Group

21 January 2018

1 reference

Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias

21 January 2018

1 reference

Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia

21 January 2018

1 reference

Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993.

21 January 2018

1 reference

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.

21 January 2018

1 reference

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

Treating childhood acute lymphoblastic leukemia without cranial irradiation

21 January 2018

1 reference

Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation

21 January 2018

1 reference

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

21 January 2018

1 reference

NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia

21 January 2018

1 reference

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

21 January 2018

1 reference

Ex vivo activation of CD56(+) immune cells that eradicate neuroblastoma

21 January 2018

1 reference

Influence of transplantation regimen on prognostic significance of high-level minimal residual disease before allogeneic stem cell transplantation in children with ALL.

21 January 2018

1 reference

A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies

21 January 2018

1 reference

Minimal residual disease quantitation in acute myeloid leukemia

21 January 2018

1 reference

Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.

21 January 2018

1 reference

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

21 January 2018

1 reference

Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia

21 January 2018

1 reference

Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation

21 January 2018

1 reference

Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia

21 January 2018

1 reference

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

21 January 2018

1 reference

High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia.

21 January 2018

1 reference

Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.12358

1 reference

release_376i7nglzncdreuszq2ujdld3u

28 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/376i7nglzncdreuszq2ujdld3u

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference